Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Disease Progression × Bevacizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 229 Carcinoma, Non-Small-Cell Lung 115 Glioblastoma 94 Breast Neoplasms 93 Ovarian Neoplasms 88 Carcinoma, Hepatocellular 70 Brain Neoplasms 64 Neoplasm Metastasis 62 Rectal Neoplasms 61 Lung Neoplasms 56 Neoplasms 52 Colonic Neoplasms 52 Glioma 46 Fallopian Tube Neoplasms 35 Carcinoma, Renal Cell 30 Pancreatic Neoplasms 29 Gliosarcoma 29 Melanoma 25 Liver Neoplasms 21 Recurrence 20 Stomach Neoplasms 19 Astrocytoma 19 Adenocarcinoma of Lung 19 Kidney Neoplasms 16 Colorectal Cancer Metastatic 16 Triple Negative Breast Neoplasms 15 Esophageal Neoplasms 15 Uterine Cervical Neoplasms 13 Endometrial Neoplasms 13 Central Nervous System Neoplasms 12

Interventions

pembrolizumab 2 fludarabine 2 Radiosurgery 2 Paclitaxel 2 Cyclophosphamide 2 Cisplatin 2 Carboplatin 2 Anthropogenic Effects 2 venetoclax 1 umbralisib 1 ublituximab 1 pazopanib 1 niraparib 1 lutetium Lu 177 dotatate 1 ibrutinib 1 grapiprant 1 fludarabine phosphate 1 famitinib 1 encorafenib 1 copanlisib 1 cemiplimab 1 capivasertib 1 camrelizumab 1 brigatinib 1 binimetinib 1 axicabtagene ciloleucel 1 avasopasem manganese 1 abexinostat 1 Transplantation, Autologous 1 Temozolomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02761070 2023-03-08

RE-GEND

Kyorin University

Phase 3 Unknown

Glioblastoma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡